Australia aims to lure foreign companies for medtech R&D (research and development)
This article was originally published in Clinica
Executive Summary
The Australian federal and state governments are openly trying to attract foreign businesses to the country by making the conditions for carrying out R&D more favourable. Australia currently imports 90% of the products that are used in the healthcare system, says Anthony Weymouth, a health and medical industry specialist for the Australian Trade Commission.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.